Table 1.
Summary of the reported cases including our patient
| Reference | Age | Sex | Thyroid function tests | Intubation | Tracheostomy | Decannulation | Levothyroxine (ROA) |
Steroids | Follow-up laryngoscopy |
| Salgado et al 13 | 63 | M | TSH: 53.28 mIU/L (normal, 0.47–4.68 mIU/L) FT4: 0.3 ng/dL (normal, 0.78–2.19 ng/dL) |
Yes | Yes | Not done at discharge | Intravenous | Hydrocortisone | Not done |
| Salgado et al 13 | 70 | M | TSH: 70.6 µIU/mL (normal, 0.35–4.94 µIU/mL) FT4 <0.1 ng/dL (normal, 0.70–1.48 ng/dL) |
Yes | Yes | 6 days | Intravenous + intravenous liothyronine |
Dexamethasone | Oedema resolved by 2 weeks |
| Batniji et al 12 | 69 | M | TSH: elevated FT4: 0.4 ng/dL (normal, 0.7–1.48 ng/dL) |
Yes | Yes | 3 weeks | Intravenous | Not given | Oedema resolved by week 2 |
| Erwin | 48 | M | TSH: 42.4 mIU/L (0–8 mIU/L) T4: 20 mmol/L (normal, 55–140 mmol/L) |
Yes | Yes | 3 weeks | PO | Not given | Persistent oedema after 2 weeks. |
| Uzunpinar | 59 | F | Not available | Yes | Yes | Not available | PO | Hydrocortisone | Oedema resolved by week 4 |
| Case | 59 | F | TSH: 14.3 IU/L (normal, 0.4–4) FT4 <0.25 ng/dL (normal, 0.8–1.8 ng/dL) |
Yes | Yes | 34 days | PO | Hydrocortisone | Not done |
F, female; FT4, free thryoxine; M, male; PO, per oral; ROA, route of administration; T4, total thryoxine; TSH, thyroid stimulating hormone.